← back to rankingCI · Cigna Corporation
Medical - Healthcare Plans · mkt cap $72.1B · calls: Q1 FY2026 vs Q4 FY2025
48.0 conviction · conf-adj 48
conf 3/10 partial
enthusiasm:24.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:0 · business_impact:8 · disruption:0 · commitment:0 · confirmation:3
Enthusiasm latest 8 / prev 5 (rising)
Cigna’s AI thesis strengthened materially in Q1 FY2026: management moved from digital tools and AI virtual assistants in Q4 FY2025 to positioning the company as a “consumer-focused and AI-enabled health services” leader. The most credible elements are tied to operational and medical-cost outcomes, including high-cost claimant prediction savings and lower call volumes. Management also put guardrails around clinical risk by saying AI is not used for clinical decision-making.
GROUNDED NEXT-FY IMPACT vs CONSENSUS
Grounded on actual base — revenue $275.0B · net income $6.0B · net margin 2.2% · diluted EPS 22.17
These are next-fiscal-year annual uplift estimates, not next-quarter numbers.
Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: medium (model's call-read: high; verdict above is the hard-data one used for ranking) · confidence: 3/10
| Claim | Figure | Arithmetic | Next-FY Rev % | Next-FY EPS % |
|---|
Predictive high-cost claimants model saves $2,000/member/yr
cost · soft | $2,000 per engaged member per year | Per-member figure is real, but NO count of engaged members is disclosed anywhere in the inputs, so aggregate saving_$ = $2,000 x (unknown members) cannot be computed. These are largely MEDICAL-COST savings accruing to clients/MLR, not a clean Cigna P&L line. Unanchored base; no revenue impact indicated. | 0 | |
20% drop in inbound calls, Cigna Healthcare US employer (digitally eligible)
productivity · soft | 20% fewer inbound calls vs 2 yrs ago | Contact-center cost saving, but no disclosed call volume or cost-per-call base to convert 20% into $. after_tax_saving = saving$ x (1-0.21) is uncomputable with saving$ unknown. % with no obtainable base -> soft. No revenue impact indicated. | 0 | |
25% reduction in inbound calls, pharmacy benefit services members
productivity · soft | 25% fewer inbound calls vs 2 yrs ago | PBM contact-center efficiency, no disclosed call volume or cost-per-call base in the inputs to size the $ saving. Unanchored -> soft. No revenue impact indicated. | 0 | |
Assumptions: All three claims are adopter-side operational AI efficiencies (predictive care management, call deflection); none is a revenue or bookings claim. Tax rate 21% would apply to any cost saving, but no member count, call volume, or cost-per-call base is disclosed anywhere in the inputs, so no aggregate $ saving can be computed and none is invented. Phasing: all claims are trailing/'to date', not forward run-rates. EPS basis: any sizable saving would be measured against consensus adjusted NI (~$7.89B, FY25 epsAvg 29.66), NOT the $5.957B GAAP base, since CI's ~2.17% GAAP net margin makes any EPS% off it a thin-denominator artifact. Current revenue base = $274.952B.
Top line: Effectively zero. No quantified revenue or bookings AI claim was provided; all three claims are internal cost/engagement efficiencies. Adopter-side revenue uplift is 0.0% against $274.952B current revenue. CI is a pure AI adopter here, not a supplier.
Bottom line: Directionally positive but unsizable from disclosures. The $2,000/member care-management saving lacks an engaged-member count; the 20%/25% call-deflection figures lack any call-volume or cost-per-call base. Without a disclosed base no figure is invented, so est_eps_uplift_pct = null. Even if sized, savings would hit the adjusted NI base (~$7.89B), not the 2.17%-margin GAAP base.
[impact n/m (all claims soft/unanchored)] Nothing is sizable into a discrete number, and what is described (claims-cost avoidance, service-cost efficiency) is exactly the affordability/SG&A leverage consensus already bakes into its trajectory: revenue $284.6B (FY26, +4.5%) and $297.8B (FY27, +4.7%), with adjusted EPS stepping 29.66 -> 30.44 (+2.6%) -> 33.46 (+9.9%). These ops efficiencies support that EPS ramp rather than exceeding it; no evidence the AI math points above consensus.
MODEL CONSENSUS (impact)
partial
Both agree all three claims are unanchored adopter-side efficiencies with no computable $; consensus leans conservative on priced_in and confidence.
Conflicts reconciled
- priced_in: X=medium vs Y=high -> used high because Y ties the efficiencies to the already-baked FY27 EPS ramp (+9.9%), the better-justified and more conservative read
- per-claim/est eps & rev pct: X=0/null mix vs Y=null -> kept rev=0 for cost claims (topline ~0) but eps_uplift_pct=null (unanchored)
- confidence: X=4 vs Y=3 -> used 3, lowered on category disagreement
| Field | Opus 4.8 | GPT-5.5 |
|---|
| Rev uplift % | – | 0 |
| EPS uplift % | – | – |
| Priced in | high | medium |
| vs analysts | unclear | unclear |
| Confidence | 3 | 4 |
| Top line | Effectively zero. All three claims are internal cost/engagement efficiencies (predictive care management, call deflection) — none is a revenue or bookings claim, so no topline uplift. CI is a pure AI adopter here, not a supplier of AI capacity. | No quantified revenue AI claim was provided; adopter-side revenue uplift is 0.0% against $274.952B current revenue. |
| Bottom line | Directionally positive but unsizable from disclosures. The $2,000/member care-management saving lacks an engaged-member count; the 20%/25% call-deflection figures lack any call-volume or cost-per-call base. Without a disclosed base I will not invent one, so est_eps_uplift_pct = null. Even if sized, savings would hit the adjusted NI base (~$7.89B), not the 2.17%-margin GAAP base, which would otherwise inflate the %. | Management quantified unit savings of $2,000/member/year and call reductions of 20% and 25%, but omitted the required member/call/cost bases, so EPS uplift cannot be computed from the supplied data. |
| Reasoning | Nothing is sizable into a discrete number, and what is described (claims-cost avoidance, service-cost efficiency) is exactly the kind of affordability/SG&A leverage consensus already bakes into its trajectory: revenue $284.6B (FY26, +4.5%) and $297.8B (FY27, +4.7%), with adjusted EPS stepping 29.66 -> 30.44 (+2.6%) -> 33.46 (+9.9%). These ops efficiencies support that EPS ramp rather than exceeding it. No evidence the AI math points above consensus. | Consensus revenue rises from $272.260B in 2025 to $284.566B in 2026, +$12.305B or +4.52%, and EPS rises from $29.65983 to $30.44113, +2.63%. The disclosed AI claims provide no computable aggregate revenue or earnings dollars to compare against that trajectory, so there is no hard evidence of upside beyond consensus. |
Rows highlighted where the two models disagreed.
QUANTIFICATIONS
Savings from predictive high-cost claimants model: $2,000 per member per year (To date, bottomline)
“To date, for those customers engaged in this model, we see an average of $2,000 per member per year in savings, resulting in the elimination of unnecessary provider and ER visits.”
Inbound call reduction for digitally eligible Cigna Healthcare U.S. employer customers: 20% drop (compared to just 2 years ago, bottomline)
“The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago.”
Inbound call reduction for pharmacy benefit services members: 25% reduction (compared to just 2 years ago, bottomline)
“The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago.”
PAST (realized)
- We expanded our suite of AI-powered digital tools to improve and personalize customer experiences.
- Already this year, we have seen a significant increase in digital registrations for our US employer businesses and decreased call volumes.
- The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago.
- To date, for those customers engaged in this model, we see an average of $2,000 per member per year in savings, resulting in the elimination of unnecessary provider and ER visits.
- The result of that is the conversion. The result of that is more value delivered, but higher satisfaction and then staying power of the conversion to the biosimilar.
CURRENT (now)
- Today, we are using Agentic AI, together with our clinical expertise to improve customer and patient experiences.
- In Pharmacy Benefit Services, we are utilizing AI to enable better care and service to our customers.
- And in Cigna Healthcare, we are using AI-enabled capabilities to improve outcomes through risk prediction models, identifying complex patients earlier and connecting them with our clinical teams.
- We do not use AI for clinical decision-making, but rather AI capabilities increase the speed and strengthen the decision quality of our highly experienced clinical teams.
- We are facilitating seamless interactions for customers based on their engagement preferences, whether that be mobile, web, text, or phone, including chat options with AI virtual assistance and easy connectivity to our service agents for even more personalized support.
FORWARD (guidance)
- Looking ahead, he is committed to further the use of data and AI to drive affordability and personalization, which in turn drives value and sustained growth.
- I'm humbled and honored to take on the role of CEO in July with a focus on the Cigna Group becoming the clear leader in consumer-focused and AI-enabled health services with an emphasis on clinically complex patients, making care more affordable and more personalized for those we serve.
- This includes leveraging AI in our [ Signature ] model to improve member communication and notifications and help patients make decisions on their care journey and enhancing our capabilities to deliver the lowest out-of-pocket cost for consumers, including with GLP-1s, where we continue to evolve as new oral solutions enter the market and prices decrease.
- One will be the way we harness data, advanced analytics and AI to drive even more personalized, affordable customer experiences; two, a relentless drive to more affordable types of care.
TRACK RECORD — PROMISE vs DELIVERY
—/100 (no quantified promises) no-quantified-promises 6 calls reviewed
Across these six Cigna calls, AI/automation references are uniformly qualitative — an AI-powered virtual assistant, provider matching, real-time cost tools, predictive capabilities, a suite of AI-powered digital tools, and Agentic AI in specialty pharmacy — with no number paired to a forward timeframe or milestone. The closest quantified claims (Clarity saving clients 'up to 10%' in medical costs, a 15% cut in prior authorizations) are product/process outcomes, not forward AI targets, so there is no quantified AI promise to judge for delivery.
PRICED-IN (REFINED)
MEDIUMEst. revisions rising · Fwd P/E 9.2 · EV/Sales 0.3x
AI claim maps to Evernorth, Cigna Healthcare
Price targets are being raised, with last-month average above last-quarter and last-year averages, while forward revenue and EPS estimates show modest growth; ratings are not clearly migrating higher, but the target trend supports a rising revision signal. Rising estimates make AI upside more priced-in, but valuation is still not stretched at 9.2x forward P/E and roughly 0.3x EV/Sales. AI efficiency or revenue upside would most plausibly flow through Evernorth and Cigna Healthcare, so the setup is mixed rather than fully priced in.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
2Q4 FY20242Q1 FY20255Q2 FY20252Q3 FY20252Q4 FY20255Q1 FY2026
AI enthusiasm across 6 calls — trend ↗ rising
AI moved from essentially absent to selective customer-service automation and a stated data/AI personalization priority under incoming leadership.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
7/10 qualitative impact material near-term · mixed evidence
Where AI matters: medical-cost management, pharmacy workflow, service automation
Cigna is deploying AI in core insurer/PBM workflows: predicting complex/high-cost patients, personalizing biosimilar conversion, processing prescriptions, and deflecting service calls. The disclosed $2,000 PMPY savings and 20%-25% call reductions are meaningful, but unsized against total members/cost base and mostly support affordability/SG&A rather than create a new revenue engine.
Caveats: Savings may accrue partly to clients/members rather than Cigna margins; No disclosed engaged-member count or call-cost base to size EPS impact; Clinical and regulatory guardrails limit automation scope; AI errors or denial-of-care perception could create reputational/regulatory risk
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 2/10
AI does not automate away Cigna's core model of risk pooling, benefit administration, PBM purchasing scale, provider networks, and regulated client relationships. It may pressure administrative opacity over time, but the most plausible effect is better cost control and member engagement inside a durable model.
OPTIONS / MARKET STRUCTURE
option liquidity: good
proxy inputs — dollar-ADV $459M · beta 0.313 · px $272.72
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 5/10 measured.
INSIDERS selling 15 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 156 new / 160 closed positions; 815 increased / 556 reduced; institutional ownership -0.13pp; -5 net 13F holders
MGMT LANGUAGE 5/10 measured AI is strategic and owned, but mostly broad future positioning with limited concrete AI-specific metrics or timelines.
commit “he is committed to further the use of data and AI to drive affordability and personalization”
commit “becoming the clear leader in consumer-focused and AI-enabled health services”
commit “This is enabling greater automation and more seamless, efficient access to care”
VERBATIM AI QUOTES
“Looking ahead, he is committed to further the use of data and AI to drive affordability and personalization, which in turn drives value and sustained growth.”
— David Cordani, Q1 FY2026
“I'm humbled and honored to take on the role of CEO in July with a focus on the Cigna Group becoming the clear leader in consumer-focused and AI-enabled health services with an emphasis on clinically complex patients, making care more affordable and more personalized for those we serve.”
— Brian Evanko, Q1 FY2026
“And I will go a bit deeper on ways that we are harnessing data, advanced analytics and AI to deliver more affordable and more personalized health care services.”
— Brian Evanko, Q1 FY2026
“By leveraging the combined power of data, advanced analytics and AI, we're able to drive greater customer and client satisfaction through improved affordability of care and greater personalization of services.”
— Brian Evanko, Q1 FY2026
“Today, we are using Agentic AI, together with our clinical expertise to improve customer and patient experiences.”
— Brian Evanko, Q1 FY2026
“This is enabling us to transform how prescriptions are processed, efficiently schedule prescription orders and proactively identify patients who may need additional service.”
— Brian Evanko, Q1 FY2026
“We do not use AI for clinical decision-making, but rather AI capabilities increase the speed and strengthen the decision quality of our highly experienced clinical teams.”
— Brian Evanko, Q1 FY2026
“In Pharmacy Benefit Services, we are utilizing AI to enable better care and service to our customers.”
— Brian Evanko, Q1 FY2026
“This includes leveraging AI in our [ Signature ] model to improve member communication and notifications and help patients make decisions on their care journey and enhancing our capabilities to deliver the lowest out-of-pocket cost for consumers, including with GLP-1s, where we continue to evolve as new oral solutions enter the market and prices decrease.”
— Brian Evanko, Q1 FY2026
“And in Cigna Healthcare, we are using AI-enabled capabilities to improve outcomes through risk prediction models, identifying complex patients earlier and connecting them with our clinical teams.”
— Brian Evanko, Q1 FY2026
“Our predictive high-cost claimants model identifies members with increasing care needs earlier in their clinical journey.”
— Brian Evanko, Q1 FY2026
“To date, for those customers engaged in this model, we see an average of $2,000 per member per year in savings, resulting in the elimination of unnecessary provider and ER visits.”
— Brian Evanko, Q1 FY2026
“The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago.”
— Brian Evanko, Q1 FY2026
“The piece I want to click down on and complement the team on, the team was able to harness effective use of AI to identify the conversion strategies in a highly personalized way, which had high NPS low friction and high continuity for both the patient and the physician.”
— David Cordani, Q1 FY2026
“We expanded our suite of AI-powered digital tools to improve and personalize customer experiences.”
— Brian Evanko, Q4 FY2025
“These include a provider matching tool to help customers find in-network providers based on their specific needs and preferences, and a real-time cost tracking tool to provide a simple breakdown of costs both before and after clinician and specialist visits.”
— Brian Evanko, Q4 FY2025
“First, we're focused on putting the customer at the center of everything we do through new innovations that are data-driven and tech-forward.”
— Brian Evanko, Q4 FY2025
“Already this year, we have seen a significant increase in digital registrations for our US employer businesses and decreased call volumes.”
— Brian Evanko, Q4 FY2025
“We are facilitating seamless interactions for customers based on their engagement preferences, whether that be mobile, web, text, or phone, including chat options with AI virtual assistance and easy connectivity to our service agents for even more personalized support.”
— Brian Evanko, Q4 FY2025
“Beyond this, we are finding new ways to utilize data and analytics, insights, and digital tools to better identify patients who need help earlier, particularly those with complex and high-cost conditions.”
— Brian Evanko, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Erin Wright): With some of the optimization in the portfolio kind of announced today, I guess, should we really think about this or really read this as you're really trying to push into specialty? Like how central is specialty to the strategy? How do we think about this in the context of your capital deployment priorities from here? And on the flip side of that, what is the commitment to other parts of the insurance business? And remind us of the synergies across the integrated model, how that aligns with this sort of new AI-enabled consumer-driven health care services company?
A: As it relates to specialty, we're already a scaled player there, and we love the space. So there should be no doubt about that. But that's not at the -- it's not trading off growth in our other growth platforms at all.
Q (Q1 FY2026, Charles Rhyee): Perhaps how much of the results we saw in the quarter were driven by formulary changes really to try to drive biosimilar adoption, which I think can be also positive for Accredo. And I'm thinking in particular around biosimilar STELARA, which I think you're also manufacturing through Quallent. Maybe talk a little bit about how the synergies between the different parts of the Evernorth business is helping in this regard?
A: The piece I want to click down on and complement the team on, the team was able to harness effective use of AI to identify the conversion strategies in a highly personalized way, which had high NPS low friction and high continuity for both the patient and the physician.